Professor Departments of Pharmacology and Anesthesiology College of Medicine University of Arizona P.O

Total Page:16

File Type:pdf, Size:1020Kb

Professor Departments of Pharmacology and Anesthesiology College of Medicine University of Arizona P.O CURRICULUM VITAE FRANK PORRECA, PH.D. Professor Departments of Pharmacology and Anesthesiology College of Medicine University of Arizona P.O. Box 245050 Tucson, Arizona 85724-5050 (520) 626-7421 (voice) (520) 626-4182 (facsimile) [email protected] (email) EDUCATION: 1975 B.S., General Science (Honors), Villanova University, Villanova, PA 1979 M.S., Biomedical Engineering, Drexel University, Philadelphia, PA 1982 Ph.D., Pharmacology, Temple University, School of Medicine, Philadelphia, PA 1982-1984 Merck Postdoctoral Research Associate, University of Arizona, Tucson, AZ PROFESSIONAL AND ACADEMIC APPOINTMENTS: 2006-2009 Director, Theme for Medical Neuroscience, College of Medicine 2005-present Associate Department Head, Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 2005-present Member, Arizona Cancer Center, University of Arizona, Tucson, AZ 2002-2003 Acting Department Head, Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 1995- present Professor of Pharmacology and Anesthesiology, College of Medicine, University of Arizona, Tucson, AZ 1991 - 1995 Professor of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 1988 - 1991 Associate Professor of Pharmacology (tenured), College of Medicine, University of Arizona, Tucson, AZ 1988-present Faculty Member, Program in Neuroscience, University of Arizona, Tucson, AZ 1985 - 1988 Assistant Professor of Pharmacology, College of Medicine, University of Arizona, Tucson, Arizona 1984 - 1985 Assistant Professor of Pharmacology, Hahnemann University Medical School, Philadelphia, PA 1982 - 1984 Merck Postdoctoral Research Associate (Dr. Thomas F. Burks), Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 1 FRANK PORRECA, PH.D. SCHOLARLY ACTIVITIES RESEARCH HIGHLIGHTS AT THE UNIVERSITY OF ARIZONA My laboratory studies mechanisms that underlie chronic pain and headache with the goal of understanding pathophysiology and contributing to the discovery of new therapies for these conditions. Several themes are found in my research including (a) the role of descending modulatory circuits in pain and headache; (b) the intersection between pain and reward pathways; (c) the mechanisms by which opioids and stress engage these circuits and (d) the discovery of molecules that can act within these circuits to provide initial research tools that will allow preclinical validation of mechanism that may be ultimately translated to clinical application. We, and others in the field have come to the realization that in spite of our advances in understanding of the neurobiology of pain, this information has not led to many novel therapies. We have recently attempted to address one part of this problem by emphasizing research that may have increased relevance to the human pain experience. Specifically, we have attempted to capture and mechanistically evaluate affective dimensions of pain, i.e., the unpleasant or aversiveness that is a fundamental component of all pain experiences. Our approach has emphasized the motivational drive resulting from the unpleasantness of pain and the understanding that relief of pain is a reward. This principle has guided a series of experiments that have allowed us to address the mechanisms by which “pain relief” occurs. We have validated this approach using both clinically effective, and clinically ineffective treatments (i.e., reverse translation) and have confirmed that relief of pain engages the classical mesocorticolimbic reward circuit only in the presence of ongoing pain. This approach has been developed so that it may serve as a platform for discovery of new medications (forward translation) for treatment of pain and headache. Throughout these studies, we have emphasized the role of descending modulatory pathways in chronic pain and headache. One outcome has been to begin to understand why chronic pain happens relatively rarely after an injury in humans. We have not limited our studies to one “type” of pain and have explored acute, inflammatory, osteoarthritic, visceral, neuropathic and headache. Our questions are guided from observations made by our clinical colleagues through their interactions with patients. This is the basis of our translational strategy and the basis for choosing molecular targets for drug discovery. Our laboratory has worked with colleagues in chemistry for nearly 30 years and our efforts have discovered molecules that have been important research tools. We have recently emphasized the discovery of molecules with multifunctional features that can act simultaneously at more than one type of receptor in order to maximize efficacy while diminishing side effects. A potentially increased therapeutic window may result in medications that can treat pain and headache in specific patient populations while maximizing quality of life. My laboratory has been continuously NIH funded since 1982. H-index is 78. EDUCATIONAL ACTIVITIES AT THE UNIVERSITY OF ARIZONA Education has been an important component of my academic life at the University of Arizona. I have served as Director, or Co-Director of the Human Neuroscience course for Medical Students from 1994- 2000, a course continuously identified as the best basic science course in the College of Medicine by 2 FRANK PORRECA, PH.D. year one Medical Students during that period. I have taught extensively in the Medical Pharmacology course for year two Medical Students and have been Director of numerous graduate courses in the Program in Pharmacology. I have organized clinical electives for medical students to promote information relevant to their medical education. I have conducted a course on drugs of abuse for undergraduate students and regularly participate in undergraduate teaching for ethics. As a member of the former Interdisciplinary Program in Pharmacology and Toxicology, I have fostered graduate education by serving as the Director of an NIH sponsored Training Grant that supported both pre- and post-doctoral students. Such support of education has benefitted faculty and students in the Colleges of Medicine and Pharmacy as well as related faculty in the multidisciplinary graduate programs in Pharmacology and Toxicology and Neuroscience. As a part of my educational activities, I have served as the primary mentor to 20 students for their Ph.D., 8 students for their M.S. and the mentor for 23 post-doctoral fellows. I have also continuously sponsored undergraduate students in my laboratory. We have 13 undergraduates pursuing research in my laboratory in 2012-2013 as well as two visiting overseas scholars. SERVICE ACTIVITIES Service activities have included local intramural, and both national and international extramural activities aimed at citizenship within the College of Medicine at the University of Arizona and to the scientific disciplines of Pharmacology and Neuroscience. Some highlights of these activities include: President of the Western Pharmacology Society in 2000. The WPS is an international society comprised of scientists from United States, Canada, Mexico and Southeastern Asia established in 1947. As President, I organized and hosted the meeting in Tucson. The meeting was extremely successful and featured world-renowned speakers including Dr. Alfred Gilman, Nobel Prize winner, Dr. Floyd Bloom, former Editor of Science, Dr. Marc Caron and Dr. Thomas F. Burks. Member of the Board of Directors of the College on Problems of Drug Dependence, an organization that fosters research into mechanisms of drug addiction and dependence. Founder and Scientific organizer of the Spring Pain Research Conference. This is a premier conference that attracts the members of the world’s best pain laboratories in both academia and in industry that is held every two years. This meeting is attended by most of the world’s senior pain scientists and is widely regarded as one of the best conference in the field. Editor in Chief, Life Sciences (2008-2012) Section Editor, Pain (2000-2012) Editorial boards of many other journals (Journal of Pain, Journal of Neuroscience). Member of the Executive Council for the Committee on Neuroscience at the University of Arizona. Member of the Dean’s Research Council at the University of Arizona. 3 FRANK PORRECA, PH.D. Chair of the Promotions and Tenure Committee of the College of Medicine, University of Arizona; Member of many other College and University Committees. Member of the Focused Excellence Study Team for Cognitive and Neuroscience Research at the request of Provost. Member of the Dean’s Cabinet (Keith Joiner, Dean). HONORS, AWARDS AND HONORARY SERVICE Institute of Medicine, National Academy of Sciences, 2011 McGill Pain Day Speaker, 2012 Benson Lecturship, Johns Hopkins University, Baltimore, MD, 2011 Blaustein Lecture, Johns Hopkins University, Baltimore, MD, 2011 Distinguished Pain Professor, Mayo Clinic Rochester, 2004 Founder’s Day Speaker, University of Arizona, 2001 President, Western Pharmacology Society, 2000 F.W. Kerr Award, American Pain Society, 2000 Benjamin Covino Pain Professor, Harvard University, 2000 Sterling Visiting Professor, Albany Medical College, 2000 Research Fellow, American Association for the Advancement of Science Multiple plenary lectures at meetings worldwide each year Scientific Organizer, Spring Pain Research Conference Board of Directors, Committee on Problems of Drug Dependence (past member) Board of Directors, Spring Brain Conference Program Committee, International Association for the Study of Pain Nominating Committee, American
Recommended publications
  • Evaluation of in Silico Approach for Prediction of Presence of Opioid Peptides in Wheat
    Evaluation of in silico approach for prediction of presence of opioid peptides in wheat This is the Accepted version of the following publication Garg, Swati, Apostolopoulos, Vasso, Nurgali, Kulmira and Mishra, Vijay Kumar (2018) Evaluation of in silico approach for prediction of presence of opioid peptides in wheat. Journal of Functional Foods, 41. 34 - 40. ISSN 1756-4646 The publisher’s official version can be found at https://www.sciencedirect.com/science/article/pii/S1756464617307454 Note that access to this version may require subscription. Downloaded from VU Research Repository https://vuir.vu.edu.au/36577/ 1 1 Evaluation of in silico approach for prediction of presence of opioid peptides in wheat 2 gluten 3 Abstract 4 Opioid like morphine and codeine are used for the management of pain, but are associated 5 with serious side-effects limiting their use. Wheat gluten proteins were assessed for the 6 presence of opioid peptides on the basis of tyrosine and proline within their sequence. Eleven 7 peptides were identified and occurrence of predicted sequences or their structural motifs were 8 analysed using BIOPEP database and ranked using PeptideRanker. Based on higher peptide 9 ranking, three sequences YPG, YYPG and YIPP were selected for determination of opioid 10 activity by cAMP assay against µ and κ opioid receptors. Three peptides inhibited the 11 production of cAMP to varied degree with EC50 values of YPG, YYPG and YIPP were 5.3 12 mM, 1.5 mM and 2.9 mM for µ-opioid receptor, and 1.9 mM, 1.2 mM and 3.2 mM for κ- 13 opioid receptor, respectively.
    [Show full text]
  • Ie-O-JY -CH2 S (56) References Cited Wherein N Is 0 to 6, X" and Y Are Independently H, Cl, F, CH, CH, CH, CH, OCH, OH, CF, OCF, NO, U.S
    US005574060A United States Patent (19) 11) Patent Number: 5,574,060 Rothman et al. (45) Date of Patent: Nov. 12, 1996 54 SELECTIVE INHIBITORS OF BIOGENIC "Hydrindene Derivatives as Potential Oral Hypoglycemic AMINE TRANSPORTERS Agents: N-Alkyl 1,2,3,3a,4,8b-Hexahydroindeno1,2-b) pyrroles', De et al., Journal of Pharmaceutical Sciences, vol. (75) Inventors: Richard Rothman, Silver Spring, Md.; 62, No. 8, Aug. 1973, pp. 1363-1364. Frank J. Carroll, Durham, N.C.; Bruce Blough, Raleigh, N.C.; Samuel (List continued on next page.) W. Mascarella, Hillsborough, N.C. Primary Examiner-Mark L. Berch (73) Assignees: The United States of America as Attorney, Agent, or Firm-Morgan & Finnegan LLP represented by the Department of 57) ABSTRACT Health and Human Services, Washington, D.C.; Office of Technology The present invention provides a compound having the Transfer, Bethesda, Md.; Research Structure: Triangle Institue, Research Triangle Park, N.C. (21) Appl. No.: 203,222 22 Filed: Feb. 28, 1994 Related U.S. Application Data H 63 Continuation-in-part of Ser. No. 105,747, Aug. 12, 1993, abandoned. wherein X, Y, and Z are independently H, Cl, Br, F, OCH, I, or an alkyl group having 1 to 6 carbon atoms; and R is (51) Int. Cl." .......................... A61K 31/40; A61K 31/47; C07D 403/06; C07D 471/08 X (52) U.S. Cl. ............................ 514/411; 546/94; 546/146; 54.6/150; 548/427: 548/428 58) Field of Search .............................. 548/427; 514/411 -ie-O-JY -CH2 S (56) References Cited wherein n is 0 to 6, X" and Y are independently H, Cl, F, CH, CH, CH, CH, OCH, OH, CF, OCF, NO, U.S.
    [Show full text]
  • Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?
    REVIEW published: 21 November 2019 doi: 10.3389/fpsyt.2019.00835 Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type? Alexei M. Bygrave 1, Kasyoka Kilonzo 2, Dimitri M. Kullmann 3, David M. Bannerman 4 and Dennis Kätzel 2* 1 Department of Neuroscience, Johns Hopkins University, Baltimore, MD, United States, 2 Institute of Applied Physiology, Ulm University, Ulm, Germany, 3 UCL Queen Square Institute of Neurology, University College London, London, United Kingdom, 4 Department of Experimental Psychology, University of Oxford, Oxford, United Kingdom Hypofunction of N-methyl-D-aspartate glutamate receptors (NMDARs), whether caused by endogenous factors like auto-antibodies or mutations, or by pharmacological or genetic manipulations, produces a wide variety of deficits which overlap with—but do not precisely match—the symptom spectrum of schizophrenia. In order to understand how NMDAR hypofunction leads to different components of the syndrome, it is necessary to take into account which neuronal subtypes are particularly affected by it in terms of detrimental Edited by: functional alterations. We provide a comprehensive overview detailing findings in rodent Bernat Kocsis, Harvard Medical School, models with cell type–specific knockout of NMDARs. Regarding inhibitory cortical cells, United States an emerging model suggests that NMDAR hypofunction in parvalbumin (PV) positive Reviewed by: interneurons is a potential risk factor for this disease. PV interneurons display a selective Margarita Behrens, Salk Institute for Biological Studies, vulnerability resulting from a combination of genetic, cellular, and environmental factors United States that produce pathological multi-level positive feedback loops. Central to this are two Vasileios Kafetzopoulos, antioxidant mechanisms—NMDAR activity and perineuronal nets—which are themselves Harvard Medical School, United States impaired by oxidative stress, amplifying disinhibition.
    [Show full text]
  • Cerebellar Toxicity of Phencyclidine
    The Journal of Neuroscience, March 1995, 75(3): 2097-2108 Cerebellar Toxicity of Phencyclidine Riitta N&kki, Jari Koistinaho, Frank Ft. Sharp, and Stephen M. Sagar Department of Neurology, University of California, and Veterans Affairs Medical Center, San Francisco, California 94121 Phencyclidine (PCP), clizocilpine maleate (MK801), and oth- Phencyclidine (PCP), dizocilpine maleate (MK801), and other er NMDA antagonists are toxic to neurons in the posterior NMDA receptor antagonistshave attracted increasing attention cingulate and retrosplenial cortex. To determine if addition- becauseof their therapeutic potential. These drugs have neuro- al neurons are damaged, the distribution of microglial ac- protective properties in animal studies of focal brain ischemia, tivation and 70 kDa heat shock protein (HSP70) induction where excitotoxicity is proposedto be an important mechanism was studied following the administration of PCP and of neuronal cell death (Dalkara et al., 1990; Martinez-Arizala et MK801 to rats. PCP (10-50 mg/kg) induced microglial ac- al., 1990). Moreover, NMDA antagonists decrease neuronal tivation and neuronal HSP70 mRNA and protein expression damage and dysfunction in other pathological conditions, in- in the posterior cingulate and retrosplenial cortex. In ad- cluding hypoglycemia (Nellgard and Wieloch, 1992) and pro- dition, coronal sections of the cerebellar vermis of PCP (50 longed seizures(Church and Lodge, 1990; Faingold et al., 1993). mg/kg) treated rats contained vertical stripes of activated However, NMDA antagonists are toxic to certain neuronal microglial in the molecular layer. In the sagittal plane, the populations in the brain. Olney et al. (1989) demonstratedthat microglial activation occurred in irregularly shaped patch- the noncompetitive NMDA antagonists,PCP, MK801, and ke- es, suggesting damage to Purkinje cells.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • RTI-4793-14, a New Ligand with High Affinity and Selectivity For
    SYNAPSE 16:59-65 (1994) RTI-4793-14, a New Ligand With High Affinity and Selectivity for the ( +)-MK801-Insensitive [3H]1 -[ 1 -( 2- thienyl)cyclohexyl]piperidine Binding Site (PCP Site 2) of Guinea Pig Brain CARL B. GOODMAN, D. NIGEL THOMAS, AGU PERT, BETSEY EMILIEN, JEAN L. CADET, F. IVY CARROLL, BRUCE E. BLOUGH, S. WAYNE MASCARELLA, MICHAEL A. ROGAWSKI, SWAMINATHAN SUBRAMANIAM, AM) RICHARD B. ROTHMAN Clinical Psychopharmacology Section, NIDMNIH Addiction Research Center, Baltimore, Maryland 21224 (C.B.G., B.E., J.L.C., R.B.R.); Biological Psychiatry Branch, NZMH (D.N.T., A.P.) and Neuronal Excitability Section, Epilepsy Research Branch, NINDS (M.A.R., S.S.), NIH, Bethesda, Maryland 20892; and Chemistry and Life Sciences, Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709-2194 (F.I.C., B.E.B., S.W.M.) KEY WORDS Phencyclidine receptor, RTI-4793-14, PCP, Biogenic amine reuptake carrier, ( + )-MK801, Guinea pig brain ABSTRACT L3HlTCP, an analog of the dissociative anesthetic phencyclidine (PCP), binds with high affinity to two sites in guinea pig brain membranes, one that is MK-801 sensitive and one that is not. The MK-801-sensitive site (PCP site 1) is associated with NMDA receptors, whereas the MK-801-insensitive site (PCP site 2) may be associated with biogenic amine transporters (BAT).Although several “BAT ligands” are known that bind selectively to PCP site 2 and not to PCP site 1 (such as indatraline), these corn- pounds have low affinity for site 2 (K, values > 1 pM). Here we demonstrate that the novel pyrrole RTI-4793-14 is a selective, high affinity ligand for PCP site 2.
    [Show full text]
  • Factors Influencing Opioid Receptor Signaling To
    FACTORS INFLUENCING OPIOID RECEPTOR SIGNALING TO ADENYLYL CYCLASE by Erica Sawyer Levitt A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmacology) in The University of Michigan 2010 Doctoral Committee: Professor John R. Traynor, Chair Professor Henry I. Mosberg Associate Professor Jeffrey R. Martens Associate Professor Roger K. Sunahara © Erica Sawyer Levitt 2010 To my husband Trevor and my mother Barbara In memory of my father Steve ii Acknowledgements Firstly, I would like to thank my mentor Dr. John Traynor for taking the time to teach me the skills required to become a successful scientist. I appreciate his patience and guidance in learning how to think critically, prepare manuscripts, write grants and deliver presentations. I am very grateful for the true interest he has taken in preparing me for the next steps of my career. Overall, I thank him for providing a challenging and rewarding graduate school experience. I would like to thank Dr. Jeffrey Martens for providing guidance scientifically as a collaborator and thesis committee member, as well as for the special effort he has taken to help me in my career. I would also like to acknowledge Dr. Henry Mosberg and Dr. Roger Sunahara for their helpful advice and guidance. To the members of the Traynor lab, present and former, thank you for assistance scientifically and for creating a collaborative work environment. Specifically, I would like to thank Kelly Bosse, Faye Bradbury, Mary Clark, Alexander Delgado, Emily Jutkiewicz, Lauren Purington, Jennifer Thomson and Qin Wang. I would like to thank the undergraduates that have contributed to the work in this thesis, Alexander Harris, Tony McClafferty, Christine Zelnik and Jason Chen.
    [Show full text]
  • Values of Several Opioid Receptor Agonists and Their Liability to Cause Depen- Dence
    Acta Pharmacologica Sinica (2010) 31: 393–398 npg © 2010 CPS and SIMM All rights reserved 1671-4083/10 $32.00 www.nature.com/aps Original Article Paradoxical relationship between RAVE (relative activity versus endocytosis) values of several opioid receptor agonists and their liability to cause depen- dence Yu-hua WANG1, 2, 3, Jian-feng SUN3, Yi-min TAO3, Xue-jun XU3, Zhi-qiang CHI3, Jing-gen LIU3, * 1School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; 2School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210046, China; 3State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China Aim: To examine the relationship between the RAVE (relative activity versus endocytosis) values of opiate agonists and their dependence liability by studying several potent analgesics with special profiles in the development of physical and psychological dependence. Methods: The effects of (–)-cis-(3R,4S,2′R) ohmefentanyl (F9202), (+)-cis-(3R,4S,2′S) ohmefentanyl (F9204), dihydroetorphine (DHE) and morphine on [35S]GTPγS binding, forskolin-stimulated cAMP accumulation, and receptor internalization were studied in CHO cells stably expressing HA-tagged μ-opioid receptors (CHO-HA-MOR). cAMP overshoot in response to the withdrawal of these compound treatments was also tested. Results: All four agonists exhibited the same rank order of activity in stimulation of [35S]GTPγS binding, inhibition of adenylyl cyclase (AC) and induction of receptor internalization: DHE>F9204>F9202>morphine. Based on these findings and the previous in vivo analgesic data obtained from our and other laboratories, the RAVE values of the four agonists were calculated.
    [Show full text]
  • Tramadol and Dihydroetorphine Produce Synergistic Analgesic Effect and Postpones Acute Opiate Tolerance in Rats
    696 Acta Physiologica Sinica, December 25, 2005, 57 (6): 696-704 http://www.actaps.com.cn Research Paper Tramadol and dihydroetorphine produce synergistic analgesic effect and postpones acute opiate tolerance in rats MING Xiao-Yun1,2,**, WANG Wei1, **, HAN Ji-Sheng1, LUO Fei 1, * 1 Neuroscience Research Institute and Department of Neurobiology, School of Basic Medicine, Peking University, Beijing 100083, China; 2 Department of Physiology, Tai’an Medical College, Tai’an 271000, China Abstract: The present study investigated whether a co-application of tramadol (TRA) and dihydroetorphine (DHE) would exert a synergy in analgesic effect and delay acute tolerance development. Intraperitoneal injection of TRA (in mg) and subcutaneous injection of DHE (in ng) were delivered in fixed proportions (1:6.25, 1:12.5, 1:25, 1:50, 1:100, and 1:200). The effect of analgesia was accessed by tail-flick test and analyzed with isobolographic analysis. For test of acute tolerance, six successive injections of either TRA (20 mg/ kg) alone, DHE (1 000 ng/kg) alone, or a combination of TRA (20 mg/kg) and DHE (250 ng/kg) were administered. We found that (1) except for 1 mg: 6.25 ng and 1 mg: 50 ng, combinations, all the other ratios produced a significant synergy in their analgesic effect; (2) the effect of analgesia induced by repeated TRA plus DHE injections lasted significantly longer, indicating a slower onset of acute tolerance. These results indicate that TRA and DHE injections in certain dose ratios can induce synergistic analgesia, which is resistant against the development of acute tolerance.
    [Show full text]
  • Outline for Controlled Substances Program
    Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent: *May 26 , 2020
    US010660887B2 United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent : *May 26 , 2020 (54 ) COMPOSITION AND METHOD FOR (56 ) References Cited TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS U.S. PATENT DOCUMENTS 6,228,875 B1 5/2001 Tsai et al. ( 71 ) Applicant : Glytech , LLC , Ft. Lee , NJ (US ) 2004/0157926 A1 * 8/2004 Heresco - Levy A61K 31/198 514/561 (72 ) Inventor: Daniel C. Javitt , Ft. Lee , NJ (US ) 2005/0261340 Al 11/2005 Weiner 2006/0204486 Al 9/2006 Pyke et al . 2008/0194631 Al 8/2008 Trovero et al. ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee , NJ (US ) 2008/0194698 A1 8/2008 Hermanussen et al . 2010/0069399 A1 * 3/2010 Gant CO7D 401/12 ( * ) Notice : Subject to any disclaimer, the term of this 514 / 253.07 patent is extended or adjusted under 35 2010/0216805 Al 8/2010 Barlow 2011/0207776 Al 8/2011 Buntinx U.S.C. 154 ( b ) by 95 days . 2011/0237602 A1 9/2011 Meltzer This patent is subject to a terminal dis 2011/0306586 Al 12/2011 Khan claimer . 2012/0041026 A1 2/2012 Waizumi ( 21 ) Appl. No.: 15 /650,912 FOREIGN PATENT DOCUMENTS CN 101090721 12/2007 ( 22 ) Filed : Jul. 16 , 17 KR 2007 0017136 2/2007 WO 2005/065308 7/2005 (65 ) Prior Publication Data WO 2005/079756 9/2005 WO 2011044089 4/2011 US 2017/0312275 A1 Nov. 2 , 2017 WO 2012/104852 8/2012 WO 2005/000216 9/2013 WO 2013138322 9/2013 Related U.S. Application Data (63 ) Continuation of application No.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]